The U.S. Food and Drug Administration (FDA) has approved a label change for Pfizer Inc.'s (NYSE: PFE) Depo-Provera contraceptive injection, adding a warning about the risk of meningioma, a type of ...
The FDA concluded that UniQure's experimental Huntington’s treatment was not providing benefit for patients based on existing clinical data ...
The head of the Food and Drug Administration on Thursday praised a plan announced by the White House earlier this week that President Trump said is designed to lower the cost of prescription drugs, ...
Pfizer has received FDA priority review for a supplemental biologics license application to expand the indication of Hympavzi (marstacimab). The proposed label expansion would include patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results